Zentalis Pharmaceuticals Statistics
Share Statistics
Zentalis Pharmaceuticals has 71.95M
shares outstanding. The number of shares has increased by 1.12%
in one year.
Shares Outstanding | 71.95M |
Shares Change (YoY) | 1.12% |
Shares Change (QoQ) | 0.77% |
Owned by Institutions (%) | 90.59% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 98 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 5.82M, so 8.11% of the outstanding
shares have been sold short.
Short Interest | 5.82M |
Short % of Shares Out | 8.11% |
Short % of Float | 16.2% |
Short Ratio (days to cover) | 7.51 |
Valuation Ratios
The PE ratio is -1.3 and the forward
PE ratio is -0.62.
Zentalis Pharmaceuticals's PEG ratio is
0.03.
PE Ratio | -1.3 |
Forward PE | -0.62 |
PS Ratio | 3.19 |
Forward PS | 0.5 |
PB Ratio | 0.64 |
P/FCF Ratio | -1.26 |
PEG Ratio | 0.03 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.32,
with a Debt / Equity ratio of 0.12.
Current Ratio | 7.32 |
Quick Ratio | 7.32 |
Debt / Equity | 0.12 |
Debt / EBITDA | -0.21 |
Debt / FCF | -0.23 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $406,174.7 |
Profits Per Employee | $-999,030.12 |
Employee Count | 166 |
Asset Turnover | 0.16 |
Inventory Turnover | n/a |
Taxes
Income Tax | 177K |
Effective Tax Rate | -0.11% |
Stock Price Statistics
The stock price has increased by -89.35% in the
last 52 weeks. The beta is 1.81, so Zentalis Pharmaceuticals's
price volatility has been higher than the market average.
Beta | 1.81 |
52-Week Price Change | -89.35% |
50-Day Moving Average | 1.42 |
200-Day Moving Average | 2.59 |
Relative Strength Index (RSI) | 40.6 |
Average Volume (20 Days) | 828,280 |
Income Statement
In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M
and earned -165.84M
in profits. Earnings per share was -2.33.
Revenue | 67.42M |
Gross Profit | 67.42M |
Operating Income | -191.19M |
Net Income | -165.84M |
EBITDA | -191.19M |
EBIT | -187.46M |
Earnings Per Share (EPS) | -2.33 |
Full Income Statement Balance Sheet
The company has 33.9M in cash and 39.58M in
debt, giving a net cash position of -5.68M.
Cash & Cash Equivalents | 33.9M |
Total Debt | 39.58M |
Net Cash | -5.68M |
Retained Earnings | -1.05B |
Total Assets | 384.02M |
Working Capital | 293.45M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -170.86M
and capital expenditures -221K, giving a free cash flow of -171.08M.
Operating Cash Flow | -170.86M |
Capital Expenditures | -221K |
Free Cash Flow | -171.08M |
FCF Per Share | -2.41 |
Full Cash Flow Statement Margins
Gross margin is 100%, with operating and profit margins of -283.57% and -245.96%.
Gross Margin | 100% |
Operating Margin | -283.57% |
Pretax Margin | -245.74% |
Profit Margin | -245.96% |
EBITDA Margin | -283.57% |
EBIT Margin | -283.57% |
FCF Margin | -253.74% |